DRTS Stock Analysis: Alpha Tau Medical | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.195m USD | 12M Return: 287.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.00M
Qual. Beats: -1
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 5.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Alpha Tau Medical Ltd. (NASDAQ: DRTS) is a clinical-stage oncology therapeutics company developing and commercializing its proprietary Alpha DaRT (diffusing alpha-emitters radiation therapy) technology for the treatment of solid tumors. As a clinical-stage biotech, the company has no approved or commercially marketed products and its value depends on the outcome of ongoing development efforts.
The Alpha DaRT technology is being evaluated in clinical trials across multiple cancer types, including skin, oral, pancreatic, prostate, lung, liver, and breast cancers, with additional preclinical work in mouse and human-derived tumor models. The company also holds a strategic collaboration agreement for prostate cancer development and commercialization, and is headquartered in Jerusalem, Israel.
- Alpha DaRT skin cancer pivotal trial data readout expected
- Strategic prostate cancer collaboration advances toward commercialization
- Cash burn accelerates as clinical pipeline expands across indications
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.57 > 0.02 and ΔFCF/TA -28.88 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.25 > 3% & CFO -26.7m > Net Income -56.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (89.7m) vs 12m ago 27.33% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -110.5 > 6 (EBIT TTM -46.3m / Interest Expense TTM 419k) |
| A: 0.65 (Total Current Assets 81.3m - Total Current Liabilities 10.4m) / Total Assets 108.8m |
| B: -1.96 (Retained Earnings -213.1m / Total Assets 108.8m) |
| C: -0.49 (EBIT TTM -46.3m / Avg Total Assets 94.9m) |
| D: 1.76 (Book Value of Equity 69.4m / Total Liabilities 39.4m) |
| Altman-Z'' = -3.54 = D |
As of July 08, 2026, the stock is trading at USD 12.76 with a total of 1,076,241 shares traded. Over the past week, the price has changed by +13.68%, over one month by +37.45%, over three months by +78.64% and over the past year by +287.69%.
Current recommended Stop Loss: 10.50 (which is 17.7% or 2.7 ATR below the current price).
Alpha Tau Medical has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy DRTS.
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.2 | 11.3% |
P/B = 17.2181
Revenue TTM = 0.0 USD
EBIT TTM = -46.3m USD
EBITDA TTM = -45.1m USD
Long Term Debt = 6.40m USD (from longTermDebt, last quarter)
Short Term Debt = 1.20m USD (from shortTermDebt, last quarter)
Debt = 22.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 7.94m
Net Debt = -57.9m USD (calculated: Debt 22.3m - CCE 80.2m)
Enterprise Value = 1.14b USD (1.20b + Debt 22.3m - CCE 80.2m)
Interest Coverage Ratio = -110.5 (Ebit TTM -46.3m / Interest Expense TTM 419k)
EV/FCF = -18.42x (Enterprise Value 1.14b / FCF TTM -61.7m)
FCF Yield = -5.43% (FCF TTM -61.7m / Enterprise Value 1.14b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 1.23m) / Revenue TTM)
Tobins Q-Ratio = 10.45 (Enterprise Value 1.14b / Total Assets 108.8m)
Interest Expense / Debt = 1.88% (Interest Expense 419k / Debt 22.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -36.6m (EBIT -46.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.74 (Total Current Assets 81.3m / Total Current Liabilities 14.2m)
Debt / Equity = 0.32 (Debt 22.3m / totalStockholderEquity, last quarter 69.4m)
Debt / EBITDA = 1.29 (negative EBITDA) (Net Debt -57.9m / EBITDA -45.1m)
Debt / FCF = 0.94 (negative FCF - burning cash) (Net Debt -57.9m / FCF TTM -61.7m)
Total Stockholder Equity = 77.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.96% (Net Income -56.9m / Total Assets 108.8m)
RoE = -73.23% (Net Income TTM -56.9m / Total Stockholder Equity 77.7m)
RoCE = -55.07% (EBIT -46.3m / Capital Employed (Equity 77.7m + L.T.Debt 6.40m))
RoIC = -36.75% (negative operating profit) (NOPAT -36.6m / Invested Capital 99.5m)
WACC = 10.93% (E(1.20b)/V(1.22b) * Re(11.11%) + D(22.3m)/V(1.22b) * Rd(1.88%) * (1-Tc(0.21)))
Discount Rate = 11.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 11.89%
[DCF] Fair Price = unknown (Cash Flow -61.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.39 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -4.0 | # QB: -1
EPS current Quarter (2026-06-30): EPS=-0.14 | Chg30d=-13.72% | Revisions=-29% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.14 | Chg30d=-9.33% | Revisions=-29% | Analysts=4
EPS current Year (2026-12-31): EPS=-0.66 | Chg30d=-28.99% | Revisions=-57% | GrowthEPS=-24.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.51 | Chg30d=-20.88% | Revisions=-50% | GrowthEPS=+21.8% | GrowthRev=+658.1%
[Analyst] Revisions Ratio: -61% (up=2, down=13)